MYC and carcinoma: Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein that was first identified as an endogenous physiological inhibitor of tumour suppressor protein phosphatase 2A (PP2A), a serine/threonine phosphatase.10 CIP2A is believed to execute its oncogenic functions mainly through stabilizing c‐Myc by inhibiting PP2A dephosphorylation of c‐Myc serine 62 (S62).10 Various independent studies have found that CIP2A is overexpressed in many types of human carcinomas, including breast, lung, gastric and hepatocellular cancers.